Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022GlobeNewsWire • 05/03/22
Journey Medical Corporation (DERM) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 04/15/22
Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley SecuritiesGlobeNewsWire • 04/04/22
Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/23/22
Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022GlobeNewsWire • 03/18/22
Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of RosaceaGlobeNewsWire • 03/17/22
QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical CorporationGlobeNewsWire • 02/11/22
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.GlobeNewsWire • 01/13/22
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 12/10/21